Abrignani
Sergio Abrignani, Serre Di Rapolano (siena) IT
Patent application number | Description | Published |
---|---|---|
20100166777 | HEMATOPOIETIC CELLS THAT EXPRESS MOSC-1 - The present invention relates to ex-vivo cells belonging to the hematopoietic system, characterized by the presence of MOSC-1 protein on cell surface, methods for isolating them and uses thereof. | 07-01-2010 |
20100183562 | SUB -POPULATION OF HEMATOPOIETIC STEM CELLS THAT EXPRESS THE CRISP-1 PROTEIN - The subject of the present invention is a sub-population of isolated hematopoietic stem cells that express the CRISP-1 gene and produce the CRISP-1 protein on the cytoplasmic membrane of the cell, their isolation and their application in the therapeutic/diagnostic/prognostic field. | 07-22-2010 |
20110038875 | HEMATOPOIETIC CELLS EXPRESSING THE PROTEIN SUSD3 AND LIGANDS FOR THE PROTEIN SUSD3 - The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein SUSD3 on the surface of said cells, to methods for preparing said cells and to ligands for SUSD3. | 02-17-2011 |
Sergio Abrignani, Serre Di Rapolano IT
Patent application number | Description | Published |
---|---|---|
20110002938 | HEMATOPOIETIC CELLS EXPRESSING THE PROTEIN KRTCAP3 AND LIGANDS FOR THE PROTEIN KRTCAP3 - The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein KRTCAP3 on the surface of said cells, to methods for isolating said cells and to ligands for KRTCAP3. | 01-06-2011 |
20120238617 | MICRORNA EXPRESSION SIGNATURE IN PERIPHERAL BLOOD OF PATIENTS AFFECTED BY HEPATOCARCINOMA OR HEPATIC CIRRHOSIS AND USES THEREOF - A method for diagnosing or prognosticating hepatocellular carcinoma, also in the early stages, or for assessing the risk of developing hepatocellular carcinoma, or for monitoring the effectiveness of an anti-tumour therapy against hepatocellular carcinoma by measuring the expression level of at least one miRNA gene product in a peripheral blood sample or in a biological fluid sample. Said method comprises measuring, in an isolated sample of peripheral blood or biological fluid, the expression level of at least one miRNA gene product, and comparing said measured expression level with a reference level. Such method can also be used to diagnose or assess the risk of developing liver cirrhosis in patients affected by chronic hepatitis, or to prognosticate the evolution of cirrhosis in patients affected by cirrhosis, or to monitor the effectiveness of a pharmacological therapy against liver cirrhosis. | 09-20-2012 |
Sergio Abrignani, Vagliagli (si) IT
Patent application number | Description | Published |
---|---|---|
20090025098 | Hepatitis C receptor protein CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. | 01-22-2009 |
20100203501 | Assay to detect HCV receptor binding - Identification of HCV receptor target cells using HCV receptor-binding ligands and cell separation by flow cytofluorimetry is described. HCV receptor target cells are employed to conduct assays for HCV receptor-binding ligands in order to identify potential HCV vaccine candidates. HCV receptor target cells are used to measure antibody neutralisation to monitor vaccine development, as a diagnostic of HCV infection and to develop neutralising antibodies for passive immunisation. | 08-12-2010 |
Sergio Abrignani, Vagliagli IT
Patent application number | Description | Published |
---|---|---|
20100143293 | T cell activation - A method for antigen independent activation of T cells comprising contacting T cells with a combination of cytokines such as two or more of interleukin-2, interleukin-6 and tumor necrosis factor α. | 06-10-2010 |
20110159039 | ELICITING HCV-SPECIFIC ANTIBODIES - Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection. | 06-30-2011 |
20120066779 | HEPATITIS C RECEPTOR PROTEIN CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. | 03-15-2012 |
Sergio Abrignani, Rapolano Terme (si) IT
Patent application number | Description | Published |
---|---|---|
20140106987 | BIOMARKERS FOR AUTOIMMUNE LIVER DISEASES AND USES THEREOF - The present invention relates to a method for diagnosis or prognosis of liver autoimmune diseases by means of detecting specific biomarkers in biological samples. The invention refers also to a method of monitoring an autoimmune liver disease pathology status after treatment with surgery and/or therapy in a subject with autoimmune liver disease, to kits and microarrays to perform said methods. | 04-17-2014 |
Sergio Abrignani, Serre Di Rapolano (si) IT
Patent application number | Description | Published |
---|---|---|
20150065375 | ACQUIRED IMMUNITY BIOMARKERS AND USES THEREOF - The present invention relates to a biomarker of immunity response for use in monitoring the acquired immunity of an immunized subject, to an in vitro method and a kit for monitoring the acquired immunity of an immunized subject. | 03-05-2015 |